Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Psychiatry. Oct 19, 2026; 16(10): 121270
Published online Oct 19, 2026. doi: 10.5498/wjp.121270
Published online Oct 19, 2026. doi: 10.5498/wjp.121270
Evolocumab intensive lipid-lowering therapy on prognosis of post-cerebral infarction depression
Yue Yang, Hong-Yan Song, Shu-Gen Wang, Department of Pharmacy, Cangzhou Central Hospital, Cangzhou 061000, Hebei Province, China
Meng-Jun Zhang, Department One of Neurology, Hejian Branch of Cangzhou Central Hospital, Cangzhou 061000, Hebei Province, China
Wan-Gen Liu, Clinical Psychological Clinic, Cangzhou Central Hospital, Cangzhou 061000, Hebei Province, China
Author contributions: Yang Y conceived and designed the study, supervised the overall research process, and drafted the manuscript; Song HY and Wang SG contributed to data collection, patient record review, and participated in manuscript revision; Zhang MJ was responsible for neurological assessment of enrolled patients and provided clinical expertise on cerebral infarction management; Liu WG conducted the psychiatric evaluations, including 17-item Hamilton Depression Rating Scale and Hamilton Anxiety Rating Scale assessments, and contributed to the interpretation of depression-related outcomes. All authors reviewed and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.
AI contribution statement: The authors declare that no AI tools were used in the preparation of this manuscript, including study design, data collection, data analysis, interpretation of results, manuscript writing, or language editing. The authors assume full responsibility for the integrity, accuracy, originality, and scientific validity of the manuscript and all submitted materials.
Supported by the Key Research and Development Program of Cangzhou, No. 23244102156.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of Cangzhou Central Hospital [No. 2024-1266-01(z)]. All procedures were conducted in accordance with the Declaration of Helsinki.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request. No additional data are available.
Corresponding author: Yue Yang, Department of Pharmacy, Cangzhou Central Hospital, No. 16 Xinhua West Road, Cangzhou 061000, Hebei Province, China. 825994864@qq.com
Received: April 22, 2026
Revised: June 10, 2026
Accepted: July 15, 2026
Published online: October 19, 2026
Processing time: 170 Days and 23.9 Hours
Revised: June 10, 2026
Accepted: July 15, 2026
Published online: October 19, 2026
Processing time: 170 Days and 23.9 Hours
Core Tip
Core Tip: This retrospective study shows that evolocumab lipid-lowering therapy greatly ameliorates the multi-dimensional prognosis in patients with post-cerebral infarction depression. The remission rates for depression nearly doubled (58.3% vs 31.9%) associated with concurrent improvements in cognition, functional independence, and rehospitalization. This parallel reduction in inflammatory markers with proprotein convertase subtilisin/kexin type 9 further supports a neuroinflammation-mediated mechanism. These results delineate evolocumab as an approach with dual therapeutic implications mitigating cardiovascular risk and neuropsychiatric sequelae in patients post-cerebral infarction.